Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

HORSHAM, Pa., Feb. 4 /PRNewswire/ -- Centocor, Inc. announced today that the Biologics License Application (BLA) for ustekinumab (CNTO 1275) has been accepted for review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic moderate to severe plaque psoriasis. Ustekinumab is a new, human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are important in regulating immune responses and that are thought to be associated with some immune-mediated inflammatory disorders, including psoriasis.

"We are pleased by the FDA's acceptance of our Biologics License Application for review of ustekinumab," stated Jerome A. Boscia, M.D., senior vice president, Clinical R&D, Centocor, Inc. "Ustekinumab has yielded promising efficacy and safety results in Phase 3 clinical trials, and we look forward to working closely with the FDA during their ongoing review of this potential new treatment for psoriasis."

Centocor, Inc. announced that it had submitted the BLA for ustekinumab in December 2007 based on its comprehensive development program including data from two large Phase 3 multicenter, randomized, double-blind, placebo- controlled trials involving nearly 2,000 patients that evaluated the safety and efficacy of ustekinumab in the treatment of moderate to severe plaque-type psoriasis. The primary endpoint of both studies was the proportion of patients who achieved at least a 75 percent reduction in psoriasis as measured by the Psoriasis Area and Severity Index (PASI 75). Acceptance of the BLA filing does not mean that a license has been issued for this product nor does it represent any evaluation of the adequacy of the data submitted in the BLA. In December 2007 the Marketing Authorization Application (MAA) for ustekinumab was submitted in Europe and is currently under review by the European Medicines Agency (
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... La Jolla, CA (PRWEB) July 23, 2014 ... adipose stem cell therapy in the US aimed at ... today announced their newest clinical study for Parkinson’s disease. ... and efficacy of stem cell therapy are paramount when ... , This clinical study makes stem cell therapy accessible ...
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 DuPont Pioneer ... business as vice president of Agricultural Biotechnology (ABT), effective ... where he served most recently as president, chief executive ... and business leadership in the seed and crop protection ... Paul E. Schickler , president of DuPont Pioneer. ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber ... biotechnology company producing sustainable chemicals, today announced that the ... full their option to purchase an additional 420,000 ... price of $12.00 per share, less underwriting discounts ... underwritten public offering of 2,800,000 shares of common ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
... 4, 2008, SAN DIEGO, Oct. 27 Neurocrine ... Gorman, President and Chief,Executive Officer of Neurocrine Biosciences will ... New York., The live presentation takes place Tuesday, ... a.m. Pacific Time (PT). The presentation will,be simultaneously webcast ...
... BioTrends Research Group, Inc. was,named one of ... Philadelphia region by the Philadelphia 100(R), a joint ... Entrepreneurs, Forum of,Greater Philadelphia, and the Philadelphia Business ... "This recognition is a testament to the ...
... Osteotech, Inc.,(Nasdaq: OSTE ) announced today ... financial results will be released Friday, November 7,2008. ... Owusu-Akyaw, President and,Chief Executive Officer, as well as ... 2008, at 9:00 a.m. Eastern time. You are ...
Cached Biology Technology:Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference 2
(Date:7/22/2014)... spot with natural tourism resources, a recent study revealed a ... Geoscience and Mineral Resources (KIGAM) indicated that there are the ... 5,000 years ago. That is the first time to actually ... volcano 5,000 years ago in the inland part of the ... The research team led by Dr. Jin-Young Lee confirmed in ...
(Date:7/22/2014)... The darker side of meerkats which sees them prevent ... explained in a new study. , Research into the desert ... pair and many adult helpers shows that the alpha ... breed. , The study shows how this way of life, ... can prove effective despite its sinister side. , Dominant ...
(Date:7/22/2014)... July 22, 2014, Cleveland: A type of immune ... diseases, such as Alzheimer,s disease and multiple sclerosis ... brain injury (TBI) and may slow the progression ... published today in the online journal Nature ... Bruce Trapp, PhD, Chair of the Department of ...
Breaking Biology News(10 mins):Jeju Island is a live volcano 2Cleveland Clinic researchers discover neuroprotective role of immune cell 2
... of North Africa,s major droughts of centuries past, reveals ... year 1179. The first multi-century drought reconstruction that ... droughts during the 13th and 16th centuries and the ... international research team figured out northwest Africa,s climate history ...
... University of Rochester Medical Center scientists discovered a defect ... earliest stages of abnormal skull development in newborns, known as ... pathways set off a cascade of events that regulate bone ... published May 25, 2010, in the journal Science Signaling ...
... Association today launched a first-of-its-kind educational tool to ... college and university professors provide evidence to support ... academic world is commonly predicated on judging a ... Sally T. Hillsman, ASA,s Executive Officer. "While teaching ...
Cached Biology News:20th century one of driest in 9 centuries for northwest Africa 220th century one of driest in 9 centuries for northwest Africa 3Stem-cell disruption induces skull deformity, UR study shows 2American Sociological Association launches first-of-its-kind teaching tool 2American Sociological Association launches first-of-its-kind teaching tool 3
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... Mouse Antibody to Human Cytokeratin TYPE ... Basic (Type II) keratins. Including epidermal cell ... at 58kD, 65kD and 67kD. Broad keratin ... oesophagus and cornea. Immunogen: ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
Biology Products: